Citi analyst Yigal Nochomovitz upgraded ProQR Therapeutics N.V. (NASDAQ: PRQR) from Neutral to Buy with a price target of $4.00..The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE